Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00221026 | Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease | PHASE2 | COMPLETED | 25 | — | — | Dec 1, 2004 | Jun 1, 2006 | Oct 19, 2016 | 15 | United States, Austria +2 |
The CDAI is a questionaire giving the change of disease acitvity.This study wil llook or a decrease in CDAI score of at least 100.
| Arm | Type | Description |
|---|---|---|
| drug | EXPERIMENTAL | ECP + Uvadex given for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| Methoxsalen +ECP | DRUG | ECP + Uvadex given at weeks 1-12 weeks. |
| Extracorporeal Photopheresis | PROCEDURE | ECP given at weeks 1 through 12. |
Inclusion Criteria: * Signed and dated informed consent must be obtained prior to conducting any study procedure. * Patients must be greater than or equal to 18 years of age. * Patients must have a body weight greater than or equal to 40 kg (88 lb). * Patients must have had Crohn's disease for at l...